| Name | Title | Contact Details |
|---|
Advanced Medical Reviews (AMR), one of the country`s top medical peer review organizations, delivers services to a diverse group of healthcare and legal organizations, including: health plans, managed care groups, workers` compensation and disability clients, TPA, IPA, Medical Groups, MSO, PPO, HMO, Medicaid and Medicare teams, hospitals and government entities. Our dedicated medical management team and staff provide a variety of review services: independent medical case review, workers` compensation, medical evaluation, utilization review, and audits. Utilizing innovative healthcare technologies, AMR delivers a single source solution for our clients` managed healthcare administration needs.
Medifit Corporate Services is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cabochon Aesthetics is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are pursuing FDA approval of psychedelic therapies to heal individual mental health and strengthen communities. We plan to build a portfolio of plant-identical compounds. Our first compound in development is mescaline.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.